Posaconazole demonstrated clinical superiority over fluconazole and itraconazole for prophylaxis of mold infections, although concerns exist regarding the high acquisition cost for posaconazole. In this respect, we sought to analyze the costs of antifungal prophylaxis in patients with acute myeloid leukemia (AML) who received prophylactic posaconazole (n = 510, 58%), itraconazole (n = 120, 14%) or fluconazole (n = 175, 20%) during induction chemotherapy. The estimated cost of antifungal prophylaxis as well as the costs of subsequent systemic antifungal therapy for treatening an invasive fungal infections (IFI) was higher in the posaconazole group compared to itraconazole and fluconazole groups. Based on the Monte Carlo simulations, the itraconazole group had the highest cost, followed by the posaconazole and fluconazole group, although the overall survival was higher in the posaconazole group as compared to the other groups. In conclusion, the cost of prophylaxis with posaconazole in AML patients compares favorably with conventional antifungal agents.

SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy / Busca, Alessandro; Lessi, Federica; Verga, Luisa; Candoni, Anna; Cattaneo, Chiara; Cesaro, Simone; Dragonetti, Giulia; Delia, Mario; De Luca, Alessio; Guglielmi, Gaspare; Tumbarello, Mario; Martino, Giordana; Nadali, Gianpaolo; Fanci, Rosa; Picardi, Marco; Potenza, Leonardo; Nosari, Annamaria; Aversa, Franco; Pagano, Livio. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - 58:12(2017), pp. 2859-2864. [10.1080/10428194.2017.1318438]

SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy

Potenza, Leonardo;
2017

Abstract

Posaconazole demonstrated clinical superiority over fluconazole and itraconazole for prophylaxis of mold infections, although concerns exist regarding the high acquisition cost for posaconazole. In this respect, we sought to analyze the costs of antifungal prophylaxis in patients with acute myeloid leukemia (AML) who received prophylactic posaconazole (n = 510, 58%), itraconazole (n = 120, 14%) or fluconazole (n = 175, 20%) during induction chemotherapy. The estimated cost of antifungal prophylaxis as well as the costs of subsequent systemic antifungal therapy for treatening an invasive fungal infections (IFI) was higher in the posaconazole group compared to itraconazole and fluconazole groups. Based on the Monte Carlo simulations, the itraconazole group had the highest cost, followed by the posaconazole and fluconazole group, although the overall survival was higher in the posaconazole group as compared to the other groups. In conclusion, the cost of prophylaxis with posaconazole in AML patients compares favorably with conventional antifungal agents.
16-mag-2017
58
12
2859
2864
SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy / Busca, Alessandro; Lessi, Federica; Verga, Luisa; Candoni, Anna; Cattaneo, Chiara; Cesaro, Simone; Dragonetti, Giulia; Delia, Mario; De Luca, Alessio; Guglielmi, Gaspare; Tumbarello, Mario; Martino, Giordana; Nadali, Gianpaolo; Fanci, Rosa; Picardi, Marco; Potenza, Leonardo; Nosari, Annamaria; Aversa, Franco; Pagano, Livio. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - 58:12(2017), pp. 2859-2864. [10.1080/10428194.2017.1318438]
Busca, Alessandro; Lessi, Federica; Verga, Luisa; Candoni, Anna; Cattaneo, Chiara; Cesaro, Simone; Dragonetti, Giulia; Delia, Mario; De Luca, Alessio; Guglielmi, Gaspare; Tumbarello, Mario; Martino, Giordana; Nadali, Gianpaolo; Fanci, Rosa; Picardi, Marco; Potenza, Leonardo; Nosari, Annamaria; Aversa, Franco; Pagano, Livio
File in questo prodotto:
File Dimensione Formato  
Busca et al_LeukLymph_2017.pdf

non disponibili

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 871.56 kB
Formato Adobe PDF
871.56 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1171221
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 3
social impact